J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Ekaterina Kim,Elisa Ten Hacken,Mariela Sivina,Astrid Clarke,Philip A. Thompson,Nitin Jain,Alessandra Ferrajoli,Zeev Estrov,Michael J. Keating,William G. Wierda,Kapil N. Bhalla,Jan A. Burger +11 more
TL;DR: GS-5829 inhibited CLL cell proliferation and induced leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC and increased synergistically in combinations with B-cell receptor signaling inhibitors, the BTK inhibitor ibrutinib, the PI3Kδ inhibitor idelalisib, and the SYK inhibitor entospletinib.
Journal ArticleDOI
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Jacqueline C. Barrientos,Jan A. Burger,John C. Byrd,Peter Hillmen,Cathy Zhou,Joi Ninomoto,Danelle F. James,Thomas J. Kipps +7 more
TL;DR: Lymphocytosis resolves in the majority of patients and does not require interruption or discontinuation of ibrutinib therapy, and in the absence of other signs of progression, does not represent disease progression.
Journal ArticleDOI
Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.
Susan O'Brien,John C. Byrd,Peter Hillmen,Steven Coutre,Jennifer R. Brown,Paul M. Barr,Jacqueline C. Barrientos,Stephen Devereux,Tadeusz Robak,Nishitha Reddy,Thomas J. Kipps,Alessandra Tedeschi,Florence Cymbalista,Paolo Ghia,Stephen Chang,Joi Ninomoto,Danelle F. James,Jan A. Burger +17 more
TL;DR: Ibrutinib is the first-in-class once daily Bruton’s tyrosine kinase inhibitor FDA approved for patients with CLL with ≥ 1 prior therapy.
Journal ArticleDOI
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex
Uri Rozovski,Uri Rozovski,Uri Rozovski,David Harris,Ping Li,Zhiming Liu,Preetesh Jain,Ivo Veletic,Alessandra Ferrajoli,Jan A. Burger,Susan O'Brien,Prithviraj Bose,Philip A. Thompson,Nitin Jain,William G. Wierda,Michael J. Keating,Zeev Estrov +16 more
TL;DR: Data show that the cellular proteins CK2, CD5, and BLNK are required for constitutive phosphorylation of STAT3 in CLL, and whether this protein complex phosphorylates other proteins or inhibiting its activity has yet to be determined.
Journal ArticleDOI
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
Uri Rozovski,David Harris,Ping Li,Zhiming Liu,Preetesh Jain,Alessandra Ferrajoli,Jan A. Burger,Prithviraj Bose,Phillip Thompson,Nitin Jain,William G. Wierda,Orit Uziel,Michael J. Keating,Zeev Estrov +13 more
TL;DR: An autonomous STAT3-driven prosurvival circuit that provides circulating CLL cells with a microenvironment-independent survival advantage is unraveled.